Dr. Paul Ridker and Dr. C. Michael Gibson Discuss: ZEUS (Primary Report of the Ziltivekimab Cardiovascular Outcomes Trial) November 7, 2026 2026 | AHA | Slides | Trial | Video Ridker ZEUS AHA 2026Download Disclosures: TBD Article Navigation In a complex real world comparison of about 500,000 patients, the addition of Repatha lowered cardiovascular outcomes 20% more than ezetimibe. Dr. Nihar Desai and Dr. C. Michael Gibson discuss the results. Dr. Steven Nissen and Dr. C. Michael Gibson Discuss: HORIZON (Effect of Pelacarsen on Cardiovascular Outcomes in Patients With Elevated Lipoprotein(a): Primary Results From the Lp(a) HORIZON Trial)
